[NCI CIRB] S1803: PHASE III STUDY OF DARATUMUMAB/rHuPH20 (NSC- 810307) + LENALIDOMIDE OR LENALIDOMIDE AS POST-AUTOLOGOUS STEM CELL TRANSPLANT MAINTENANCE THERAPY IN PATIENTS WITH MULTIPLE MYELOMA (MM) USING MINIMAL RESIDUAL DISEASE TO DIRECT THERAPY DURATION (DRAMMATIC STUDY)
This study is being done to answer the following questions:
1. Will adding the drug daratumumab/rHuPH20 to the usual maintenance treatment with lenalidomide after stem cell transplant help myeloma patients survive longer?
2. For patients who have no evidence of myeloma in their bone marrow (patients who do not have “minimum residual disease” [MRD-negative]), should maintenance therapy be stopped after 2 years?
autologous stem-cell transplant (ASCT)
- Participant must be between 18 and 75 years old
- Participants must have had or will have an autologous stem cell transplant (ASCT)
18 - 75
Healthy Volunteers Needed
Duration of Participation
Participants will be on study for up to 15 years from the time of study entry through follow up.
Knight Information Line - email@example.com or 503-494-1080